Impel Pharmaceuticals (IMPL) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free IMPL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineImpel Pharmaceuticals Inc. (IMPLQ)finance.yahoo.com - March 13 at 2:48 PMImpel Pharma Mulls Sale, Signs Stalking Horse Deal; Files For Chapter 11 Protectionmarkets.businessinsider.com - December 20 at 12:51 AMImpel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Salefinance.yahoo.com - December 20 at 12:51 AMAdrian Adams steps down as CEO of Seattle's Impel Pharmaceuticalsbizjournals.com - November 6 at 2:15 AMAnalysts Offer Insights on Healthcare Companies: Impel Pharmaceuticals (IMPL) and Relay Therapeutics (RLAY)markets.businessinsider.com - October 9 at 12:25 PMImpel Pharmaceuticals Announces Exploration of Strategic Alternativesfinance.yahoo.com - October 5 at 12:41 PMImpel Pharmaceuticals (IMPL) Receives a Hold from JonesTradingmarkets.businessinsider.com - September 14 at 9:29 AMmarketbeat.com - September 13 at 10:43 AMmarketbeat.com - September 13 at 10:39 AMWhy Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?msn.com - September 8 at 8:35 AMJonesTrading Reaffirms Their Hold Rating on Impel Pharmaceuticals (IMPL)markets.businessinsider.com - August 22 at 6:02 PMImpel Pharma Shares Tumble 46% After Breaching Terms of Credit Agreementmarketwatch.com - August 16 at 4:51 PMImpel Pharma (NASDAQ:IMPL) Plummets on Viability Concernsmsn.com - August 16 at 9:12 AMWhy Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?investorplace.com - August 16 at 9:09 AMBiotech Catches Major Premarket Bidtheglobeandmail.com - July 5 at 2:26 PM84P.SG - Impel Pharmaceuticals Incfinance.yahoo.com - July 3 at 7:37 PMDirector at Impel Pharmaceuticals Acquires Company Stock Options Worth 13,222 Sharesbenzinga.com - June 21 at 5:30 PMImpel Pharmaceuticals Board Member Awarded $15K Worth of Stock Optionsbenzinga.com - June 21 at 12:30 PMImpel Pharmaceuticals Director Awarded $15K Worth of Stock Optionsbenzinga.com - June 21 at 12:30 PMImpel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Societyfinance.yahoo.com - June 15 at 9:29 AMmarketbeat.com - May 17 at 9:48 AMImpel Pharmaceuticals Inc. (IMPL)uk.finance.yahoo.com - May 17 at 8:15 AMImpel Pharmaceuticals First Quarter 2023 Earnings: Misses Expectationsfinance.yahoo.com - May 13 at 12:29 PMRecap: Impel Pharmaceuticals Q1 Earningsmsn.com - May 12 at 4:26 PMImpel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 12 at 9:26 AMEarnings Outlook For Impel Pharmaceuticalsmsn.com - May 11 at 7:13 PMImpel Pharmaceuticals gets new CFOmsn.com - May 10 at 1:11 PMImpel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officerfinance.yahoo.com - May 10 at 8:10 AMInvestors in Impel Pharmaceuticals (NASDAQ:IMPL) from a year ago are still down 67%, even after 26% gain this past weekfinance.yahoo.com - May 5 at 1:52 PMImpel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023finance.yahoo.com - May 5 at 8:52 AMImpel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medicationsfinance.yahoo.com - April 26 at 11:46 AMImpel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meetingfinance.yahoo.com - April 11 at 8:38 AMImpel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results: Here's What Analysts Are Forecasting For This Yearfinance.yahoo.com - March 30 at 8:31 AMImpel Pharmaceuticals Inc. (NASDAQ:IMPL) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - March 27 at 2:50 AMImpel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%finance.yahoo.com - March 26 at 3:19 PMImpel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimatesmsn.com - March 24 at 12:46 PMImpel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updatefinance.yahoo.com - March 24 at 12:46 PMImpel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023finance.yahoo.com - March 17 at 8:36 AMImpel Pharmaceuticals to Participate in Upcoming Investor Conferences in Marchfinance.yahoo.com - March 3 at 8:41 PMImpel Pharma says reducing headcount by 16%, eliminating pipeline programsseekingalpha.com - February 24 at 10:16 PMWhy Domino's Pizza Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - February 23 at 3:29 PMImpel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunityfinance.yahoo.com - February 22 at 7:17 PMImpel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunityfinance.yahoo.com - February 22 at 7:17 PMOcular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last?nasdaq.com - February 14 at 8:38 AMImpel Pharmaceuticals Inc. (NASDAQ:IMPL) to Post FY2027 Earnings of $1.16 Per Share, Wedbush Forecastsmarketbeat.com - January 26 at 3:12 AMImpel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcriptseekingalpha.com - November 14 at 8:56 PMImpel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue Estimatesnasdaq.com - November 14 at 8:56 PMImpel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 14 at 10:35 AMInvestors in Impel Pharmaceuticals (NASDAQ:IMPL) have unfortunately lost 67% over the last yearfinance.yahoo.com - November 14 at 10:35 AMImpel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Dayfinance.yahoo.com - November 8 at 7:53 PM Get Impel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IMPL and its competitors with MarketBeat's FREE daily newsletter. Email Address One trade. One ticker. One week. (Ad)Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. IMPL Media Mentions By Week IMPL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMPL News Sentiment▼0.000.44▲Average Medical News Sentiment IMPL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMPL Articles This Week▼00▲IMPL Articles Average Week Get Impel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IMPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SPRC News Today BDRX News Today EVFM News Today EVLO News Today BLPH News Today SBFM News Today CMRA News Today ADTX News Today SXTC News Today GRI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMPL) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Impel Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
